Abstract

Objective: It has been demonstrated that ghrelin plays a major role in the regulation of GH secretion and food intake. These actions make ghrelin a strong candidate for the treatment of GH deficiency, anorexia and cachexia. However, only preliminary studies have been performed to assess ghrelin administration in humans. In this study, we have conducted a double-blind, randomized, placebo-controlled trial to investigate the pharmacokinetics, safety, and endocrine and appetite effects of ghrelin in young healthy volunteers.

Design: Eighteen male volunteers were randomly assigned into three groups of six subjects: low- and high-dose ghrelin groups, who received intravenous injections of 1 and 5 μg/kg ghrelin (acylated form) respectively, and a placebo group who were injected with mannitol instead of ghrelin.

Results: Acylated ghrelin disappeared more rapidly from plasma than total ghrelin, with elimination half life ($t_{1/2}$) of 9 –13 and 27– 31 min respectively. The number of subjects that experienced adverse effects did not significantly differ among the three groups, and all adverse effects were transient and well tolerated. Both the low and high doses of ghrelin strongly stimulated GH release ($C_{max,0–90\min}$: 124.2 ± 63.9 and 153.2 ± 52.2 ng/ml for 1 and 5 μg/kg ghrelin respectively). Slight alterations of blood glucose and insulin levels after the injection were observed. Although not statistically significant, ghrelin administration tended to increase hunger sensation in a dose-dependent manner.

Conclusions: These results suggest that ghrelin is safe, and that clinical trials may be started to assess the usefulness of ghrelin for the treatment of disorders related to GH secretion and appetite.

European Journal of Endocrinology 150 447–455

Introduction

Ghrelin is a peptide hormone which was discovered in 1999 and is an endogenous ligand for the growth hormone (GH)-secretagogue receptor (GHS-R) (1). Ghrelin consists of 28 amino acids and contains a unique fatty acid modification, n-octanoylation, at Ser 3. This acylation is essential for most of ghrelin’s biological activities, although unacylated ghrelin has been recently reported to exert biological activities on cell proliferation (2, 3). Ghrelin is mainly produced in the stomach and circulates in the blood at a considerable plasma concentration. Expression of ghrelin is also detectable in the hypothalamus, intestine, pituitary, placenta and other tissues (1, 4–6). In addition, GHS-R expression has been demonstrated in several tissues other than the hypothalamus and pituitary (6–8). Reflecting the wide expression patterns of both the ligand and the receptor, ghrelin is now known to play a role in a number of different physiological processes. For example, ghrelin increases GH secretion, feeding and body weight when administered centrally or peripherally to rodents (1, 9–11). Additionally, in humans, intravenous administration of ghrelin increases GH secretion and food intake (12–18). Thus, ghrelin elicits multiple effects in both the brain and peripheral tissues (19, 20).

These unique effects of ghrelin and GHS will be invaluable for the development of novel treatments and disease diagnostics (21–23). Clinical trials have already been performed to assess the utility of GHS for the treatment of short stature (24), GH deficiency (24, 25), obesity (26) and catabolic conditions (27). However, only preliminary studies have been performed...
to assess the possible benefits of ghrelin administration to humans (12–18, 28–31). Indeed, these studies include only one non-randomized phase I clinical trial (15). In this study, we performed a phase I/II trial to investigate the pharmacokinetics, safety and efficacy of ghrelin with regards to induction of hormone secretion and appetite in healthy volunteers.

Materials and methods

Healthy volunteers

Eighteen male volunteers between 21 and 25 years old participated in our phase I/II study, which was conducted at Kyoto University Hospital (Kyoto, Japan). The volunteers were judged to be healthy by standard clinical and laboratory investigations including chest X-ray, 12-lead electrocardiogram, prick allergen testing and blood pressure responses to postural changes. In addition, they were not suffering from any medical diseases or receiving medical treatment and had no past history of malignant disorders. They were randomly assigned to three groups: low- and high-dose ghrelin groups and a placebo group (see below). The baseline characteristics of each group of volunteers are summarized in Table 1. There were no significant differences in age, body mass index (BMI) or other parameters between the three groups. The study protocol was approved by the ethics committee on human research at the Kyoto University Graduate School of Medicine (project proposal number 400), and the studies were performed according to Good Clinical Practice (GCP) standards. Written informed consent was obtained from the volunteers prior to enrolment.

Study design

The study was randomized, double-blinded and placebo-controlled. Over a week-long screening period, eligible volunteers received either a bolus intravenous injection of ghrelin (1 μg/kg for the low-dose group or 5 μg/kg for the high-dose group) or a placebo injection (3.75% D-mannitol). Treatment assignments were randomized centrally to a 1:1:1 ratio, in blocks of three. The randomization code was generated by a statistician from the Department of Clinical Trial Design and Management and was maintained there until all data had been collected and the study was unblinded. Neither the investigators nor the volunteers were aware of the treatment assignments in the study.

Study drug

Human ghrelin was synthesized as previously described (1, 12, 15, 17). The acylated peptide was dissolved in 3.75% D-mannitol to yield a final concentration of 40 or 400 μg/ml. These solutions were then filtered and stored at −20°C in sterile vials. Examinations conducted by the Japan Food Research Laboratories (Tokyo, Japan) found no traces of endotoxin in the ghrelin solutions, and a pyogen test based on the Japanese Pharmacopoeia was negative.

Assessment of safety

Overall safety was assessed on the following day and at 8 days post-infusion. At all study visits, vital signs (pulse rate and blood pressure), haematology, blood chemistry and urinalysis were measured. All volunteers were hospitalized during the night of drug administration.

Measurement of plasma ghrelin, GH, insulin-like growth factor-I (IGF-I), glucose and insulin concentrations

On infusion days, subjects were fasted overnight and had two intravenous cannulae (one for infusion and one for blood sampling) implanted at 0900 h (t = −45 min). Blood samples for hormone and glucose analyses were drawn from an indwelling catheter fixed in a forearm vein at −15, 0, 15, 30, 45, 60 and 90 min after drug administration. Pulse rate and blood pressure readings were taken at every blood drawing. N-RIAs and C-RIAs (radioimmunoassay (RIA) for the ghrelin N- and C-terminals, respectively) for plasma ghrelin were performed using anti-human ghrelin-(1–11) and -13–28 sera respectively, as described previously (32, 33). The anti-human ghrelin-(1–11)

Table 1 Summary of volunteer baseline characteristics (means±s.d.).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Placebo (n = 6)</th>
<th>1.0 μg/kg ghrelin (n = 6)</th>
<th>5.0 μg/kg ghrelin (n = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>23.3±1.5</td>
<td>22.8±1.7</td>
<td>22.0±0.0</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>20.1±1.9</td>
<td>22.0±2.0</td>
<td>20.9±0.8</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>62.8±6.0</td>
<td>64.0±8.4</td>
<td>63.2±5.7</td>
</tr>
<tr>
<td>Serum GH (ng/ml)</td>
<td>6.2±8.2</td>
<td>0.8±1.0</td>
<td>1.9±3.9</td>
</tr>
<tr>
<td>Serum IGF-I (ng/ml)</td>
<td>275.7±67.6</td>
<td>262.8±98.5</td>
<td>287.8±62.3</td>
</tr>
<tr>
<td>Plasma glucose (mg/dl)</td>
<td>82.9±3.4</td>
<td>84.8±7.1</td>
<td>78.7±6.6</td>
</tr>
<tr>
<td>Serum insulin (U/ml)</td>
<td>4.1±2.2</td>
<td>3.4±2.0</td>
<td>4.3±1.2</td>
</tr>
<tr>
<td>Plasma total ghrelin (fmol/ml)</td>
<td>221.6±46.3</td>
<td>149.2±66.8</td>
<td>188.0±62.6</td>
</tr>
<tr>
<td>Plasma active ghrelin (fmol/ml)</td>
<td>18.3±5.4</td>
<td>12.0±5.3</td>
<td>20.7±10.1*</td>
</tr>
</tbody>
</table>

* n = 5; the active ghrelin level of one patient was eliminated because the sample was stored improperly.
antiserum specifically recognizes the \( n \)-octanoylated portion of ghrelin and does not recognize des-\( n \)-octanoylated ghrelin, while the anti-human ghrelin-(13–28) antiserum recognizes both \( n \)-octanoyl-modified and des-\( n \)-octanoylated ghrelin equally. Thus, by using both assays we were able to measure the total ghrelin plasma concentration and the concentration of the active form only. Serum GH, IGF-I and insulin were measured by immunoradiometric assay (IRMA) (FALCO Biosystems Ltd, Kyoto, Japan). IGF-I was measured before infusion, and also 1 and 8 days after the infusion.

**Assessment of hunger sensation**

Visual analogue scales rating hunger (possible scores 0–10 cm) were completed pre-infusion at −15 min, at infusion (0) and 15, 30, 45, 60 and 90 min after the administration of the study drug (34, 35). Positions on the scale were measured in centimetres and millimetres by an investigator who was unaware of the treatment groups. The change (\( \Delta \)) in the visual analogue score at time \( t \) was calculated by subtracting the visual analogue score at 0 min from the score at time \( t \) in the same subject.

**Pharmacokinetic and statistical evaluations**

The pharmacokinetic evaluation for ghrelin was performed using the one-compartment model (36). The peak plasma concentration \( (C_{\text{max}}) \) was calculated with PK Solutions version 2 (Summit Research Services, CO, USA) and S-PLUS Version 4.0 (Mathematical Systems Inc., Japan). The area under the curve (AUC) for the entire 90 min blood-sampling period was calculated by the trapezoidal method. The \( t_{1/2} \) was calculated as \( \ln 2/z \), where \( z \) is the terminal elimination rate constant. Pharmacokinetic parameters were analysed descriptively with the calculation of geometric means and 95% confidence intervals (CI). Comparisons between groups administered with different study drugs were performed using the Wilcoxon rank sum test with the Bonferroni correction. Other statistical analyses were performed with SAS version 8 (SAS Institute Inc., Cary, NC, USA). A two-tailed \( P \) value was used, with the required level of significance being \( P < 0.05 \).

**Results**

**Pharmacokinetics**

Mean plasma concentration-vs-time profiles of ghrelin after administration are shown in Fig. 1. Descriptive statistics of the pharmacokinetic parameters of ghrelin are summarized in Table 2. After administration of 1 and 5 µg/kg ghrelin, total plasma ghrelin concentrations reached 1058.7 and 6597.9 fmol/ml respectively, and had an elimination \( t_{1/2} \) of 27–31 min. Active ghrelin at 15 min accounted for 42.2–52.3% of total ghrelin, and displayed a \( t_{1/2} \) of 9–13 min, roughly one-third that of total ghrelin. The active ghrelin levels of one patient administered with 5 µg/kg ghrelin were eliminated from the analysis because his samples were stored improperly.

**Assessment of safety**

Several adverse events were reported by ghrelin-injected subjects (Table 3), but all of these complaints
were transient and well tolerated. One subject administered with 1 mg/kg ghrelin experienced mild abdominal discomfort and a flushed sensation for a few minutes; another subject injected with 5 mg/kg ghrelin indicated a flushed sensation and a marked episode of perspiration in the upper part of the trunk that lasted for nearly an hour. Two subjects injected with 1 mg/kg ghrelin experienced somnolence. One subject administered with 5 mg/kg ghrelin manifested fever, pharyngeal redness and diarrhoea with abdominal pain and leukocytosis; however, specialist infectious disease physicians and investigators diagnosed him as having acute bacterial enterocolitis that was unrelated to the medication. No significant changes in heart rate or blood pressure were recorded following the injections. Ghrelin did not significantly alter the clinical blood chemistries or complete blood count, to the best of our ability to detect. Although mild glucosuria was found in a low-dose ghrelin subject on the day after the injection, it disappeared after 1 week and was also found in a placebo subject; this subject also returned to normal after 1 week. Another placebo subject showed mild proteinuria on the day after the injection, but did show any abnormal urinalysis after 1 week. Since both subjects did not show glucosuria at the screening or 1 week after injection, they were judged to be healthy. Abnormal urinary findings were not found in high-dose subjects. In total, the number of subjects that experienced adverse effects was not significantly different among the three groups (Table 3).

GH and IGF-I release

The GH responses to ghrelin are shown in Fig. 2A and Table 4. Ghrelin strongly stimulated GH release. No significant difference between the low- and high-dose ghrelin groups was observed in the peak or AUC GH release, suggesting that a submaximal-dose ceiling effect occurs even at 1 mg/kg ghrelin in normal young males. Administration of ghrelin did not induce a significant increase in plasma IGF-I (Fig. 2B).

Plasma glucose and serum insulin

Ghrelin administration resulted in significantly higher plasma glucose levels 15 min after injection with either 1 or 5 mg/kg ghrelin, although no dose dependency was observed (Fig. 3A). At 90 min after injection of 5 mg/kg ghrelin, plasma insulin demonstrated a statistically significant decrease (Fig. 3B). No significant

---

**Table 2** Pharmacokinetic parameters of intravenous bolus administration of ghrelin. Results are given as means with 95% confidence intervals in parentheses.

<table>
<thead>
<tr>
<th>Pharmacokinetic Parameter</th>
<th>Placebo (n = 6)</th>
<th>1.0 μg/kg ghrelin (n = 6)</th>
<th>5.0 μg/kg ghrelin (n = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cmax,0–90 min (fmol/ml)</td>
<td>230.7 (187.8, 273.5)</td>
<td>1058.7 (882.6, 1234.8)</td>
<td>6597.9 (5919.0, 7276.6)</td>
</tr>
<tr>
<td>AUC0–90 min (10^3 fmol min/ml)</td>
<td>18.92 (16.51, 21.34)</td>
<td>45.91 (35.64, 56.17)</td>
<td>54.6 (43.80, 65.41)</td>
</tr>
<tr>
<td>AUC0–90 min (10^3 fmol min/ml)*</td>
<td>18.92 (16.51, 21.34)</td>
<td>45.91 (35.64, 56.17)</td>
<td>54.6 (43.80, 65.41)</td>
</tr>
<tr>
<td>t1/2 (min)</td>
<td>1.0</td>
<td>1.91 (1.58, 2.23)</td>
<td>1.91 (1.58, 2.23)</td>
</tr>
</tbody>
</table>

* AUC0–90 min in one-compartment model.

**Table 3** Adverse events.

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Placebo (n = 6)</th>
<th>1.0 μg/kg ghrelin (n = 6)</th>
<th>5.0 μg/kg ghrelin (n = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal discomfort</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Malaise</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fever</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Glucosuria</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Leukocytosis</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Hypoesthesia</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Somnolence</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Throat redness</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Hyperhidrosis</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Flushing</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>4</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>Number of subjects (Incidence, 95% CI)</td>
<td>3 (0.50, 0.12 ~ 0.88)</td>
<td>2 (0.33, 0.04 ~ 0.78)</td>
<td>2 (0.33, 0.04 ~ 0.78)</td>
</tr>
</tbody>
</table>
differences were observed in the ΔAUC of glucose or insulin levels following ghrelin injection (Table 4).

**Hunger sensation**

Ghrelin administration tended to increase the hunger sensation in a dose-dependent manner, particularly within 45 min of injection (Fig. 4A). However, the difference between groups, based on evaluation by change in visual analogue score, did not reach statistically significance levels even at 15 min (Fig. 4B). In the placebo group, two of the six subjects did not show any change in hunger score. In contrast, all of the subjects in both the low- and high-dose ghrelin groups reported changes in their scores (data not shown).

**Discussion**

We performed a double-blind, randomized, placebo-controlled trial on 18 young healthy volunteers to investigate the pharmacokinetics, safety and efficacy of ghrelin in inducing hormone secretion and appetite. Since the number of subjects studied may be too low to obtain thorough information about these effects of ghrelin, we adopted this study design to minimize the disadvantage or bias that is caused by the rather low number of subjects. This is the first report to simultaneously analyse the pharmacokinetics of both total and active ghrelin, and is a larger clinical trial of ghrelin administration than the only previous clinical trial (15). The total plasma ghrelin concentrations recorded at 15 min following administration of either 1 or 5 μg/kg ghrelin (3.2 and 20 ng/ml respectively) appeared to be comparable to those recorded during a previous trial which examined the administration of 10 μg/kg ghrelin (°60 ng/ml) (15). Roughly 42.2–52.3% of the total ghrelin at 15 min was active ghrelin. The elimination t1/2 of total plasma ghrelin was 27–31 min, nearly three times as long as that of active ghrelin, reflecting the rapid degradation of acylated active ghrelin in the plasma (33).

Several adverse effects were reported following ghrelin administration in our study, including abdominal discomfort, flushing, somnolence and hyperhidrosis (Table 3). Previous studies reported similar adverse

---

Table 4 GH, glucose and insulin responses to ghrelin administration (means±S.D.).

<table>
<thead>
<tr>
<th>GH (ng/ml)</th>
<th>ΔAUC0–90 min</th>
<th>Glucose (mg/dl)</th>
<th>Insulin (U/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt;,0–90 min</td>
<td>AUC&lt;sub&gt;0–90 min&lt;/sub&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo (n = 6)</td>
<td>6.91±6.2</td>
<td>344.2±307.1</td>
<td>-82.5±138.4</td>
</tr>
<tr>
<td>1.0 μg/kg ghrelin (n = 6)</td>
<td>124.2±63.9</td>
<td>6474.3±3688.4</td>
<td>152.5±187.2</td>
</tr>
<tr>
<td>5.0 μg/kg ghrelin (n = 6)</td>
<td>153.2±52.2</td>
<td>8564.4±9630.6</td>
<td>166.25±465.8</td>
</tr>
</tbody>
</table>

1 P = 0.005: placebo vs 1.0 μg/kg ghrelin; placebo vs 5.0 μg/kg ghrelin.
2 P = 0.005: placebo vs 1.0 μg/kg ghrelin; placebo vs 5.0 μg/kg ghrelin.
3 Not significant (NS): placebo vs 1.0 μg/kg ghrelin; placebo vs 5.0 μg/kg ghrelin.
4 NS: placebo vs 1.0 μg/kg ghrelin; placebo vs 5.0 μg/kg ghrelin.
effects, but listed bowel movements and warm sensations instead of abdominal discomfort and flushing (Table 5). However, these are probably two different descriptions of the same phenomena. Because these adverse effects have been observed in multiple studies, it is likely that they are directly ghrelin related. All of these complaints, however, were transient and well tolerated. Ghrelin did not significantly alter clinical blood chemistries or complete blood count as far as we were able to discern.

In this study, 1 μg/kg of ghrelin appeared to result in a ceiling effect on the GH response in young men; C_{max,0–90 min} of GH was 124.2 ± 63.9 ng/ml. This observation is in contrast to previous studies that were performed with the same size of groups (each group, n = 6); the 1 μg/kg dose was observed to elicit a significantly lower response than the 5 μg/kg dose (12, 17). The GH response to the 5 μg/kg dose appears to be slightly higher than those of the previous studies; C_{max,0–90 min} of GH was 153.2 ± 52.2 vs 107.7 ± 23.9 (12) or 109.8 ± 26.2 ng/ml (17) (Table 4). Although the reasons for this discrepancy are unclear, it may be explained by the fact that the volunteers in this study were younger than those in previous studies (22 vs. 31 years). In fact, age-related variations in GH response to ghrelin or GHS in humans have been reported (30, 37). To confirm this, it is necessary to carry out further studies using more subjects, including elderly people.

There are only three reports by two groups concerning the effects of ghrelin on glycaemia and insulin secretion in humans (28, 30, 38). Broglio et al. (28)
found that administration of 1 or 3.3 μg/kg ghrelin led to a transient inhibition of insulin secretion coupled with hyperglycaemic effects in normal male adults. However, in those studies, glucose remained persistently elevated from 15 to 165 min, and absolute insulin levels were reduced from 30 min with a nadir at 45 min. In addition, there were significant changes observed in glucose and insulin AUC. Arosio et al. (38) also found a significant increase in glucose concentrations at 15 and 30 min, and a significant decrease (41% decrease from the baseline) in insulin concentrations at 60 min. Our results differ greatly from these previous studies, for we found that the ghrelin-induced glucose increase was much shorter and less pronounced, while the insulin decrease occurred later and to a lesser degree. Since the previous studies did not observe a significant change in insulin levels following ghrelin administration in young women, this insulin response may vary depending upon the type of group tested (30). Moreover, the effect of ghrelin on insulin secretion has been inconsistent in both human and animal models (39), as both inhibitory (28, 30, 40) and stimulatory (41–43) effects have been reported. Further studies are necessary to clarify the effect of ghrelin on glucose metabolism.

Ghrelin is the first circulating hormone demonstrated to stimulate appetite in man. Wren et al. (18) showed that a 17 ng/kg per min intravenous infusion of ghrelin for 270 min enhanced appetite and food intake in humans. The total amount of ghrelin infused in this study was 4.5 μg/kg. Similarly, in this study, ghrelin administration tended to increase the hunger sensation in a dose-dependent manner, particularly in the early phase after injection, although the difference between groups did not reach statistically significant levels. In addition, while two of the six subjects in the placebo group did not show any change in hunger score, all of the subjects in both the low- and high-dose groups reported increases in hunger. To confirm this orexigenic effect of ghrelin, a study using larger-sized groups or a cross-over study will be necessary. Although Weikel et al. (31) reported that the subjects in their study did not feel a change in appetite after 4 × 0.66 μg/kg of ghrelin administered hourly as intravenous boluses, that dose may have been too low to stimulate appetite. Because tests for appetite are subjective and variable among subjects, only double-blind tests such as this study may yield reliable findings.

In summary, we have confirmed the safety and hormonal effects of ghrelin in a randomized, double-blind test. No serious adverse effects were found. Ghrelin markedly stimulated GH release, slightly modulated blood glucose and insulin levels, and tended to increase the hunger sensation in a dose-dependent manner. These results suggest that ghrelin may have therapeutic and diagnostic potential in patients with disorders related to GH secretion and appetite.

Acknowledgements

We would like to thank Dr Hashida for preparing the drugs for this study, Dr Nakai for valuable advice regarding the measurement of visual analogue scores and Dr Ichiyama for consultation concerning infection of one subject and a critical review of laboratory tests. We would also like to thank Mr Asada, Mr Irikida, Mr Nakagawa, Mrs Sugiyama, Miss Sawai, Miss Nakatani and Miss Kouchi for their excellent secretarial assistance.

This study was supported by funds from the Ministry of Education, Science, Culture, Sports and Technology of Japan. There is no conflict of interest that would prejudice the impartiality of the research.

References

37 Arosio M, Ronchi CL, Gebbia C, Cappiello V, Beck-Pecoz P & Peracchi M. Stimulatory effects of ghrelin on circulating


Received 13 October 2003
Accepted 3 December 2003